MedPath

JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMET L.L.C.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Study of the Safety and Effectiveness of JNJ-16269110 (R256918) in Overweight and Obese Patients

Phase 2
Completed
Conditions
Obesity
Nutritional and Metabolic Diseases
Metabolic Diseases
Nutrition Disorders
Overweight
Interventions
Drug: placebo
First Posted Date
2008-02-25
Last Posted Date
2014-05-13
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
321
Registration Number
NCT00622765

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.

Phase 3
Completed
Conditions
Arthralgia
Bunion
Hallux Valgus
Pain
Interventions
First Posted Date
2008-02-13
Last Posted Date
2014-05-09
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
901
Registration Number
NCT00613938

A Study Evaluating Effects of Intranasal JNJ-17166864 on Symptoms of Allergic Rhinitis in Adults

Phase 2
Completed
Conditions
Allergic Rhinitis
Interventions
Drug: Placebo
First Posted Date
2008-01-30
Last Posted Date
2015-04-29
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
74
Registration Number
NCT00604123

A Study to Evaluate the Effect of Food on Levofloxacin Pharmacokinetics From an Oral Solution Formulation

Phase 1
Completed
Conditions
Healthy
First Posted Date
2008-01-28
Last Posted Date
2016-12-22
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
24
Registration Number
NCT00601432

Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia

Phase 3
Completed
Conditions
Schizophrenia
Interventions
First Posted Date
2008-01-10
Last Posted Date
2014-06-24
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
1221
Registration Number
NCT00589914

To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia

Phase 3
Terminated
Conditions
Ventilator-Associated Pneumonia
Interventions
First Posted Date
2008-01-10
Last Posted Date
2012-12-28
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
274
Registration Number
NCT00589693

An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer

Phase 2
Completed
Conditions
Breast Neoplasms
Interventions
First Posted Date
2007-12-24
Last Posted Date
2014-02-25
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
127
Registration Number
NCT00580112
© Copyright 2025. All Rights Reserved by MedPath